MedTrace Logo

Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS

NCT02339805 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-07-07

No results posted yet for this study

Summary

This is a prospective descriptive monocentric study whose purpose is to describe the clonal evolution of the mutational pattern in cfDNA of a cohort of patients with Diffuse Large B-Cell Non-Hodgkin Lymphomas (DLBCL) before, during and after standard treatment

Conditions

  • Non Hodgkin Lymphoma

Interventions

OTHER

next generation sequencing

DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.

DEVICE

Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)

tumor Assessment tool during the study

Sponsors & Collaborators

  • U918 ( Inserm unit)

    collaborator UNKNOWN

  • Centre Henri Becquerel

    lead OTHER

Principal Investigators

  • Fabrice Jardin, Professor · Centre Henri Becquerel

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-01
Primary Completion
2015-07-31
Completion
2016-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02339805 on ClinicalTrials.gov